Myfenax 500 mg film-coated tablets
Sponsors
Kezar Life Sciences Inc., AstraZeneca AB, F. Hoffmann-La Roche AG
Conditions
Autoimmune diseaseLupus Nephritis (LN)MET-drivenunresectable and locally advanced or metastatic Papillary Renal Cell Carcinoma
Phase 2
A Phase 2b, Randomized, Controlled Double-blind, Multicenter Study Comparing the Efficacy and Safety of Zetomipzomib (KZR-616) 30 mg or 60 mg with Placebo in Patients with Active Lupus Nephritis
CompletedCTIS2022-502227-22-00
Start: 2023-10-25End: 2024-10-17Target: 82Updated: 2024-04-24
A Phase II, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescent Patients with Active Class III or IV Lupus Nephritis, Including an Evaluation of Open Label Safety and PK in a Cohort of Pediatric Patients (Aged 5 To < 12)
RecruitingCTIS2023-505825-15-00
Start: 2021-10-29Target: 10Updated: 2025-05-03
Phase 3
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Obinutuzumab in Patients with ISN/RPS 2003 Class III or IV Lupus Nephritis
Active, not recruitingCTIS2023-503628-22-00
Start: 2020-07-16Target: 52Updated: 2026-01-27
SAMETA A Phase III, Open Label, Randomised, 3-Arm, Multi-Centre Study of Savolitinib plus Durvalumab versus Sunitinib and Durvalumab Monotherapy in Participants with MET-Driven, Unresectable and Locally Advanced or Metastatic Papillary Renal Cell Carcinoma (PRCC) (SAMETA)
RecruitingCTIS2022-503105-38-00
Start: 2021-10-22Target: 62Updated: 2025-06-06